The price gap is real and it is large. At retail, brand name Wegovy costs approximately $1,350 per month. Compounded semaglutide from a telehealth platform typically costs $150–$350 per month. That is a $1,000 or more monthly difference for what many patients are told is "the same medication."
The "same medication" claim is mostly true — but not entirely. And the ways in which it is not entirely true are the ones that matter for making an informed decision.
This article explains exactly what compounded semaglutide is, how it differs from brand name Wegovy, what the documented safety risks are, what the legal status is in 2026, and under what circumstances the comparison changes.
One editorial note before we begin: WeightRxGuide.com covers FDA-approved brand-name telehealth providers. That is not because compounded semaglutide is necessarily unsafe — it is because our editorial mission is to help readers navigate the FDA-approved landscape, where quality and safety standards are most clearly defined. This article presents the full picture on compounded semaglutide honestly and completely.
What Is Compounded Semaglutide?
Drug compounding is the process by which a licensed pharmacy prepares a customized medication using active pharmaceutical ingredients (APIs) and excipients, rather than dispensing a commercially manufactured drug product. Compounding has a legitimate and long-established role in medicine — preparing medications at custom doses, in alternative delivery forms, or without specific inactive ingredients that a patient is allergic to.
Compounded semaglutide applies this framework to the active molecule in Wegovy and Ozempic: a pharmacy purchases semaglutide API (typically as a powder), combines it with other ingredients, and packages it in vials or syringes for injection. The result is a medication that uses the same active molecule as Wegovy but is not manufactured by Novo Nordisk and has not been reviewed by the FDA as a finished drug product.
Compounding pharmacies in the US operate under two regulatory frameworks:
503A pharmacies — Traditional state-licensed compounding pharmacies. They operate pursuant to individual patient prescriptions, are regulated primarily by state boards of pharmacy (not the FDA), and are not required to follow the FDA's current Good Manufacturing Practice (cGMP) standards or to report adverse events to the FDA. They produce patient-specific formulations in smaller batches.
503B outsourcing facilities — Larger-scale compounding operations that voluntarily register with the FDA. They can produce compounded medications without individual prescriptions, are subject to FDA inspection, and must follow cGMP standards. They also must report adverse events to the FDA. They face more regulatory scrutiny than 503A pharmacies, but their products still do not undergo the pre-market safety and efficacy review that FDA-approved drugs receive.
The practical hierarchy: Brand name Wegovy > 503B > 503A in terms of regulatory oversight and manufacturing quality assurance.
The Chemical Difference: Semaglutide Base vs. Salt Forms
This is the most technical aspect of the comparison and the one most frequently glossed over in popular coverage.
Brand name Wegovy and Ozempic use semaglutide as a free base — the specific molecular form that underwent clinical trials and received FDA approval.
Many compounded semaglutide products use semaglutide sodium or semaglutide acetate — chemically related compounds that are not identical to the free base and have different molecular weights.
Semaglutide acetate, in particular, is a concern: semaglutide acetate has not been validated for human use and is not the same as the semaglutide sodium or semaglutide free base used in clinical trials and FDA-approved products.
Why does this matter? The clinical trial data — the STEP trials showing 15% average weight loss with semaglutide — was generated using the specific free base formulation in brand name products. Assuming that a different salt form will produce identical clinical outcomes is an assumption, not an established fact. The salt form affects how the molecule behaves during manufacturing, how stable it is, and potentially how it is absorbed and metabolized. These differences have not been studied in large-scale clinical trials.
This is not a theoretical concern. Dosing errors with compounded semaglutide have led to hospitalizations for severe nausea, vomiting, dehydration, and pancreatitis. The FDA documented these adverse events occurring when patients measure from multidose vials using incorrect syringes.
Manufacturing Quality: What the FDA Actually Oversees
Brand name Wegovy is manufactured in Novo Nordisk facilities under stringent FDA current Good Manufacturing Practice (cGMP) regulations. Every batch undergoes extensive analytical testing before release: purity, potency, sterility, particulate matter, and stability under various storage conditions. The manufacturing process itself — the specific equipment, procedures, and environmental controls — is reviewed and approved by the FDA. Adverse events must be reported to the FDA. The labeling specifies the exact approved dose, administration technique, and safety information based on clinical trial data.
Compounded semaglutide quality varies dramatically by pharmacy:
At 503B outsourcing facilities: cGMP compliance is required and FDA inspections occur. Many reputable 503B facilities maintain excellent quality standards with rigorous sterility testing and batch-level certificates of analysis (COAs). This tier offers meaningful quality assurance — significantly better than 503A — but still does not match the pre-market FDA review that Wegovy's manufacturing received.
At 503A pharmacies: Quality assurance depends almost entirely on state board of pharmacy oversight, which varies significantly in stringency. Many 503A pharmacies maintain good practices; others do not. Adverse events are not required to be reported to the FDA. Quality control is less standardized.
At unregulated online sources: The FDA has flagged a rising number of counterfeit and adulterated semaglutide products sold online. These are the highest-risk products and should be avoided entirely.
Novo Nordisk testing found over 24% impurities in some compounded samples, underscoring that compounded medications do not always meet the purity standards that brand name manufacturing is designed to guarantee.
The Clinical Trial Data Gap
This is perhaps the most important distinction for a patient trying to evaluate whether compounded semaglutide "works."
Brand name semaglutide (Wegovy): The STEP clinical trial program enrolled over 15,000 patients across multiple phase 3 randomized controlled trials. The trials generated detailed data on average weight loss by dose (15% at 2.4 mg), side effect rates and severity, cardiovascular outcomes (the SELECT trial), specific populations (adolescents, patients with T2D, patients with OSA), and what happens after discontinuation. This is the evidence base that supports prescribing decisions.
Compounded semaglutide: No large controlled studies have evaluated compounded versions of semaglutide. The assumption that compounded products will produce the same outcomes relies on the belief that they are pharmaceutically equivalent to the FDA-approved medication, which may not always be the case when different chemical forms, manufacturing methods, or quality control processes are used.
The clinical effectiveness argument for compounded semaglutide rests on an assumption of pharmaceutical equivalence — same active molecule, therefore same clinical effect. This is a reasonable assumption if the compound genuinely uses semaglutide free base at the correct potency in a sterile formulation from a quality-controlled 503B facility. It is a less reasonable assumption if the compound uses a different salt form, incorrect potency, or comes from a less rigorously controlled source.
The absence of clinical trial data also means the safety profile specific to compounded products is not established. If a compounded product has higher-than-expected impurities or incorrect potency, the known safety profile of semaglutide from the STEP trials does not apply.
The Legal Status in 2026: What Changed
The legal history of compounded semaglutide tracks directly to the FDA shortage list. When FDA designates a drug as "in shortage," compounding pharmacies gain a specific legal pathway to produce copies of that drug. Wegovy was added to the FDA shortage list in March 2022; Ozempic in August 2022.
In February 2025, the FDA determined that the shortage of semaglutide injection products had been resolved. This triggered enforcement deadlines for compounding pharmacies. State-licensed pharmacies operating under Section 503A had until April 22, 2025, to cease production of compounded semaglutide that essentially copies the FDA-approved products. Outsourcing facilities under Section 503B had until May 22, 2025.
What this means in 2026:
Most compounding of semaglutide — the wide-scale, shortage-justified production that made compounded GLP-1s ubiquitous from 2022–2025 — is no longer legally authorized.
Compounding pharmacies may still legally prepare semaglutide in specific circumstances:
- At non-commercially-available doses — doses that are not available in standard FDA-approved configurations
- When a patient has a documented allergy to an inactive ingredient in the brand name product
- For specific patient clinical needs that cannot be met by commercial products
The Outsourcing Facilities Association filed a lawsuit challenging the FDA's shortage resolution determination. As of early 2026, this litigation continues and creates some legal uncertainty about the scope of enforcement. Availability of compounded semaglutide has decreased meaningfully but has not been eliminated entirely. Some platforms that previously offered standard-dose compounded semaglutide have transitioned to brand name; others continue to offer compounded at non-standard doses with prescriber documentation of clinical need.
Compounded Tirzepatide: The Same Story
Everything above applies equally to compounded tirzepatide (the active ingredient in Zepbound and Mounjaro). Zepbound was on the FDA shortage list and the shortage was resolved in a similar timeframe. The same legal restrictions on compounding apply. The same quality variability concerns exist. And the Eli Lilly lawsuit against Mochi Health — alleging mass dose changes without individual provider consultation — specifically involved compounded tirzepatide, illustrating the clinical governance risks that can accompany high-volume compounded medication programs.
When the Comparison Changes: The Role of Insurance and Self-Pay Pricing
The dramatic cost difference between compounded and brand name semaglutide is most relevant when you are paying out of pocket at retail pharmacy prices. When insurance or manufacturer savings programs are in the picture, the comparison changes substantially.
With commercial insurance + savings card: Brand name Wegovy at $0–$25/month per the Novo Nordisk savings card is cheaper than most compounded programs ($150–$350/month), and you get the FDA-approved product. The cost argument for compounded largely disappears.
Without insurance, at NovoCare self-pay pricing: Brand name Wegovy at $199/month (intro) or $349/month (maintenance) is meaningfully more expensive than compounded ($150–$250/month) but represents a dramatically better quality-adjusted comparison than retail vs. compounded. The price gap is real but narrower than the retail comparison suggests.
Without insurance, at retail: $1,350/month brand name vs. $150–$350/month compounded — this is where the price argument for compounded is strongest, and where most patients who chose compounded during the shortage period made their decision.
With Medicare starting July 2026: The Medicare GLP-1 Bridge at $50/month for brand name Wegovy or Zepbound makes brand name significantly cheaper than compounded for eligible Medicare patients.
A Framework for the Decision
This is not a decision WeightRxGuide.com makes for you — WeightRxGuide covers FDA-approved brand-name providers as our editorial focus. But patients and clinicians making this decision in 2026 have legitimate factors to weigh:
Arguments for brand name Wegovy:
- FDA-approved with full pre-market safety and efficacy review
- Manufactured under rigorously enforced cGMP with mandatory adverse event reporting
- Uses the specific molecular form studied in 15,000+ patient clinical trials
- Pre-filled auto-injector eliminates manual dosing errors
- Insurance coverage possible — can dramatically reduce cost
- Manufacturer savings programs make cash-pay pricing competitive
- Legal status unambiguous
Arguments that led patients to compounded semaglutide:
- Price at retail was prohibitive — $1,350/month vs. $150–$350/month
- Shortage made brand name unavailable for years
- From a reputable 503B pharmacy with a COA, same active molecule
- Clinically similar outcomes reported in real-world use
Things that should not factor into the decision:
- Marketing claims that compounded semaglutide is "clinically proven" — it is not; the STEP trials used brand name product
- Claims that compounded is "the same thing" without acknowledgment of the chemical form, manufacturing, and regulatory differences
- Price comparisons against brand name retail list price rather than NovoCare self-pay or insurance pricing
If compounded semaglutide is under consideration, minimum requirements:
- Source only from a 503B registered outsourcing facility
- Confirm the pharmacy uses semaglutide free base or sodium — not semaglutide acetate
- Request batch-level certificates of analysis (COAs) documenting potency and sterility
- Ensure prescribing provider oversight throughout treatment
- Verify the pharmacy's current regulatory and legal compliance status
The Safety Summary
The safety of semaglutide as an active molecule is well-established through the STEP trial program. The safety questions specific to compounded formulations relate to manufacturing quality and regulatory oversight, not the molecule itself.
Lowest risk: Brand name Wegovy from Novo Nordisk
Lower risk (but non-zero): Compounded semaglutide from a 503B registered facility using semaglutide free base, with batch COAs, under prescriber supervision, from a pharmacy with current regulatory compliance
Moderate risk: Compounded from a 503A pharmacy with limited external oversight
High risk: Compounded from unverified online sellers, unknown pharmacies, or products with no COA documentation
Do not use: Products sold online without a valid prescription, from unregistered pharmacies, or without any quality documentation
The FDA's position is unambiguous: compounded semaglutide is not FDA-approved and has not been reviewed for safety, effectiveness, and quality. Without FDA approval, these products are made by compounding pharmacies that are not required to track, evaluate, or report side effects and adverse events.
For the brand-name FDA-approved GLP-1 programs we cover on this site, see our full provider comparison — all 16 platforms listed prescribe FDA-approved brand-name medications.